OakChart

Caribou Biosciences Inc

CRBUHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.3907-0.0197 (-4.80%)
2026-11-12 05:10 CET
Market cap
42.21 USD m
Revenue, TTM
9.44 USD m
Net income, TTM
-102.47 USD m
Free cash flow, TTM
-92.99 USD m
EPS diluted, TTM
-1.03
P/E
-
Compare

Price

CRBU against its 20, 50 and 200-day averages
2050200beat
0.501.001.502.002.5018.7M37.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CRBUclose 0.3920-day 0.4650-day 0.88200-day 1.590.3952w high

84.3% under the 52-week high of 2.49 on 1 Jun 2026. 52-week low 0.37 on 11 Nov 2026. Last 15 sessions, 58.1% high to low

Volume 1.10× normal · the line is the 50-bar volume average

Profile

CRBU
52-week range, 0% of the way up
0.392.49

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

IndexRUT
Employees97
IPOJul 23, 2021
Beta2.48
ATR, 14d0.05
Rel volume1.10
Short float15.15%
Insider own9.00%
Inst own46.14%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap42.21M
Enterprise Value-26.25M
Income-102.47M
Sales9.44M
Book/sh0.71
Cash/sh0.88
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees97
IPOJul 23, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S4.47
P/B0.55
P/C0.45
P/FCF-
EV/EBITDA-
EV/Sales-2.78
Quick Ratio4.97
Current Ratio4.97
Debt/Eq0.34
LT Debt/Eq0.32
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.03
EPS next Y-0.94
EPS next Q-0.10
EPS this Y47.04%
EPS next Y-11.88%
EPS next 5Y-2.05%
EPS past 3/5Y1.01% -22.62%
Sales past 3/5Y-6.95% -2.03%
EPS Y/Y TTM39.34%
Sales Y/Y TTM1.60%
EPS Q/Q16.19%
Sales Q/Q-26.89%
EarningsNov 05 AMC
EPS/Sales Surpr.4.58% 0.63%

Ownership

Insider Own9.00%
Insider Trans0.00%
Inst Own46.14%
Inst Trans8.99%
ROA-64.44%
ROE-93.80%
ROIC-100.94%
Gross Margin73.04%
Oper. Margin-1140.55%
Profit Margin-1085.00%
SMA20-15.90%
SMA50-55.58%
SMA200-75.37%
Trades-

Technical

Shs Outstand108.04M
Shs Float98.31M
Short Float15.15%
Short Ratio5.57
Short Interest14.89M
52W High2.49 -84.31%
52W Low0.39 0.13%
Volatility11.00% 9.21%
ATR (14)0.05
RSI (14)27.37
Beta2.48
Rel Volume1.10
Avg Volume2.67M
Volume2,939,658

Performance

Perf Week-12.08%
Perf Month-16.87%
Perf Quarter-75.73%
Perf Half Y-81.57%
Perf YTD-75.43%
Perf Year-82.56%
Perf 3Y-89.85%
Perf 5Y-98.10%
Perf 10Y-
Recom2.20
Target Price11.75
Prev Close0.41
Price0.39
Change %-4.80%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Oct 08, 2026DowngradeHH.C. WainwrightBuy → Neutral
Oct 07, 2026DowngradeRRBC Capital MktsOutperform → Sector Perform$1+156.0%
Oct 07, 2026DowngradeLLeerink PartnersOutperform → Market Perform$1+156.0%
Jun 03, 2024DowngradeEEvercore ISIOutperform → In-line$13 → $3+667.9%
Nov 08, 2023InitiatedCCantor FitzgeraldNeutral
Oct 31, 2023InitiatedEEvercore ISIOutperform$13+3,227.4%
Jul 11, 2023InitiatedTTruistBuy$23+5,786.9%
Feb 18, 2022InitiatedRRBC Capital MktsOutperform$22+5,530.9%
Dec 01, 2021InitiatedOOppenheimerOutperform$36+9,114.2%
Nov 30, 2021InitiatedHH.C. WainwrightBuy$28+7,066.6%

Peers

Mkt cap
TickerCompanyMkt cap
ALLOAllogene Therapeutics Inc311.85M
CLLSCellectis ADR99.82M
CRSPCRISPR Therapeutics AG4.44B
FATEFate Therapeutics Inc195.12M
AUTLAutolus Therapeutics plc ADR328.71M
DTILPrecision Biosciences Inc255.61M
IPSCCentury Therapeutics Inc315.07M
NKTXNkarta Inc106.12M
SANASana Biotechnology Inc686.16M
EDITEditas Medicine Inc367.33M

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Kelly Timothy PChief Technology OfficerFeb 25 '26Sale1.936,22812,02073,125Feb 27 04:01 PM
RUHI AHMAD KHANOfficerFeb 24 '26Proposed Sale1.966,93813,598Feb 25 09:42 PM
BARBARA G MCCLUNGOfficerFeb 24 '26Proposed Sale1.966,93813,598Feb 25 09:41 PM
TIMOTHY KELLYOfficerFeb 25 '26Proposed Sale1.936,22812,051Feb 25 05:16 PM
Kelly Timothy PChief Technology OfficerFeb 24 '26Sale1.963,1476,16879,353Feb 24 08:54 PM
MCCLUNG BARBARA GChief Legal OfficerFeb 24 '26Sale1.966,93813,598481,564Feb 24 08:54 PM
Khan Ruhi AhmadChief Business OfficerFeb 24 '26Sale1.966,93813,598104,998Feb 24 08:54 PM
Albertson Tina M.Chief Medical OfficerFeb 24 '26Sale1.961,0662,08968,523Feb 24 08:53 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.250-0.262-0.2501.611.605
2026Q22026-08-13-0.240-0.324-0.2401.502.285
2026Q12026-05-07-0.260-0.310-0.2622.402.216
2025Q42026-03-05-0.280-0.310-0.2803.942.218
2025Q32025-11-12-0.300-0.354-0.2952.202.278
2025Q22025-08-12-0.350-0.403-0.5822.671.744
2025Q12025-05-08-0.430-0.434-0.4322.351.755
2024Q42025-03-10-0.390-0.418-0.3892.082.117
2024Q32024-11-06-0.380-0.450-0.3832.023.086
2024Q22024-08-06-0.420-0.458-0.4173.463.057
2024Q12024-05-07-0.460-0.411-0.4622.402.426
2023Q42024-03-11-0.390-0.368-0.3903.563.957
2023Q32023-11-07-0.120-0.416-0.11923.663.296
2023Q22023-08-08-0.480-0.495-0.4813.763.086
2023Q12023-05-09-0.460-0.481-0.4583.502.756
2022Q42023-03-09-0.440-0.462-0.4423.703.076

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-2.110-2.122-1.1119.6010.94
2022FY-1.640-1.691-1.63513.9012.43
2023FY-1.380-1.370-1.38334.4834.90
2024FY-1.650-1.658-1.6519.9910.26
2025FY-1.590-1.588-1.59011.169.39
2026FY--0.842--7.10
2027FY--0.942--6.13
2028FY--1.690--6.15
2029FY--2.750--16.50
2030FY--3.325--95.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-104031.700.003.00
2026Q4S2026-11-065032.260.004.50
2026Q4S2026-10-285022.900.005.51
2026Q4S2026-10-075222.900.005.51
2026Q4S2026-10-054213.250.005.51
2026Q4S2026-09-234304.153.005.51
2026Q4S2026-08-145303.822.505.51
2026Q4S2026-07-2260018.842.5097.60
2026Q4S2026-06-1462118.842.5097.60
2026Q4S2026-05-0872116.512.5097.60
2026Q4S2026-03-0660019.112.50100
2026Q4S2025-11-132002.752.503.00
2026Q4S2025-11-112002.752.503.00
2026Q4S2025-11-102002.752.503.00

Estimate history

EPS, annual-0.391-0.572-1.111-1.635-1.383-1.651-1.586-1.0298
Period2019202020212022202320242025TTM
EPS, quarterly-0.383-0.389-0.432-0.582-0.295-0.28-0.262-0.24-0.248
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual5.78812.3619.59813.85134.4779.99411.1599.44
Period2019202020212022202320242025TTM
Sales, quarterly2.0242.0772.3532.6672.1983.9412.3971.4991.607
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual59.97159.97160.26361.02988.44992.37995.144108.037
Period2019202020212022202320242025MRQ
Shares, quarterly90.55392.37993.00593.12393.46895.14496.951105.996108.037
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue9.4411.169.9934.4813.859.6012.365.79
Cost of Goods Sold Incl. D&A2.553.653.933.523.640.98--
Gross Profit6.907.516.0730.9510.218.61--
Selling, General and Administrative Excl. Other114.61143.71172.68147.01116.6175.5947.5939.34
Research and Development84.72109.44130.15112.0882.2352.2634.4223.64
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-107.71-136.19-166.62-116.06-106.40-66.98-36.12-34.30
Interest Expense0.000.00---0.010.020.00
Unusual Expense0.0021.31-2.151.29-2.30-0.160.000.00
Net Income Before Taxes-103.02-148.68-149.11-101.88-99.35-66.60-36.13-30.97
Income Taxes-0.55-0.55-0.010.190.070.32-1.82-7.54
Consolidated Net Income-102.47-148.12-149.10-102.07-99.42-66.92-34.31-23.43
Net Income From Continuing Operations-102.47-148.12-149.10-102.07-99.42-66.92-34.31-23.43
Net Income-102.47-148.12-149.10-102.07-99.42-66.92-34.31-23.43
EPS (Recurring)-0.95-1.43-1.67-1.37-1.66-1.11-0.57-0.39
EPS (Basic, Before Extraordinaries)-1.03-1.59-1.65-1.38-1.64-1.11-0.57-0.39
EPS (Diluted)-1.03-1.59-1.65-1.38-1.64-1.11-0.57-0.39
EBITDA-105.17-132.55-162.69-112.53-102.76-66.00-35.22-33.55
Non-Operating Income (Expense)5.488.8315.3515.484.750.230.023.34
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.0710.0213.2010.869.262.440.730.90
Price To Sales Ratio14.4613.3114.3712.2727.5794.75--
Gross Margin73.0467.3460.7189.7873.7189.75--
Operating Margin-1,140.55-1,220.49-1,667.16-336.63-768.17-697.84-292.24-592.69
Net Margin-1,085.00-1,327.40-1,491.95-296.05-717.79-697.26-277.55-404.82
Shares Outstanding108.0495.1492.3888.4561.0360.2659.9759.97
Market Capitalization42.2142.21143.98506.71383.09908.30896.26-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.611.502.403.942.202.672.352.08
Cost of Goods Sold Incl. D&A0.590.620.650.680.631.171.171.18
Gross Profit1.020.871.753.261.571.501.190.89
Selling, General and Administrative Excl. Other28.6626.2128.0331.7130.9736.9344.1039.77
Research and Development21.3518.9420.6123.8222.4027.6935.5330.46
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-27.64-25.34-26.28-28.45-29.40-35.43-42.91-38.88
Interest Expense0.000.000.000.000.000.000.00-
Unusual Expense0.000.000.000.000.0020.86-0.33-0.22
Net Income Before Taxes-26.61-24.28-25.09-27.04-27.55-54.10-39.99-35.50
Income Taxes0.000.000.00-0.550.000.000.00-0.01
Consolidated Net Income-26.61-24.28-25.09-26.49-27.55-54.10-39.99-35.49
Net Income From Continuing Operations-26.61-24.28-25.09-26.49-27.55-54.10-39.99-35.49
Net Income-26.61-24.28-25.09-26.49-27.55-54.10-39.99-35.49
EPS (Recurring)-0.25-0.24-0.26-0.28-0.30-0.42-0.43-0.39
EPS (Basic, Before Extraordinaries)-0.25-0.24-0.26-0.28-0.30-0.58-0.43-0.39
EPS (Diluted)-0.25-0.24-0.26-0.28-0.30-0.58-0.43-0.39
EBITDA-27.05-24.71-25.63-27.77-28.77-34.26-41.75-37.69
Non-Operating Income (Expense)1.031.061.202.201.852.192.593.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.162.482.360.082.933.133.880.40
Price To Sales Ratio14.4617.7116.2613.4723.3912.858.5314.50
Gross Margin63.2958.3172.9282.6971.2956.2450.4942.99
Operating Margin-1,720.10-1,690.39-1,096.37-721.97-1,337.58-1,328.38-1,823.76-1,871.69
Net Margin-1,656.00-1,619.88-1,046.52-672.11-1,253.32-2,028.42-1,699.58-1,708.71
Shares Outstanding108.04106.0096.9595.1493.4793.1293.0092.38
Market Capitalization42.21174.56183.61148.61216.98117.1984.92143.98

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments139.34209.54328.83247.66375.8315.9541.07
Short Term Receivables2.983.253.864.668.125.163.98
Inventories0.000.000.000.000.000.000.00
Other Current Assets2.916.596.167.927.243.1911.96
Total Current Assets145.23219.38338.84260.25391.1924.3157.01
Net Property, Plant & Equipment24.4339.2940.4534.914.893.504.33
Total Investments and Advances3.5549.1751.3377.0745.407.630.00
Deferred Tax Assets4.267.548.7610.502.852.48-
Other Assets2.155.471.591.540.880.610.59
Total Assets179.63320.85440.97384.27445.2038.5361.93
Short Term Debt Incl. Current Port. of LT Debt1.201.441.580.970.260.850.53
Accounts Payable5.782.483.121.153.992.602.54
Income Tax Payable-----0.010.01
Other Current Liabilities18.4326.7323.6126.0221.588.947.00
Total Current Liabilities25.4130.6528.3028.1325.8312.3910.08
Long Term Debt26.0325.0625.9126.780.0042.2541.32
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities4.268.089.3210.883.322.640.65
Other Liabilities1.754.109.0417.6128.234.692.42
Total Liabilities57.4667.9072.5783.4057.3861.9754.47
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity122.17252.95368.40300.87387.82-23.447.46
Total Shareholders Equity122.17252.95368.40300.87387.82-23.447.46
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity122.17252.95368.40300.87387.82-23.447.46
Total Liabilities & Stockholders Equity179.63320.85440.97384.27445.2038.5361.93
Book Value Per Share1.282.744.174.936.44-0.390.12
Tangible Book Value Per Share1.282.744.174.936.44-0.390.12
Full-Time Employees971471581379967-
Price to Book Ratio0.550.511.271.182.342.21-
Return on Assets-59.19-39.14-24.74-23.97-27.67-68.30-
Return on Equity-78.97-47.99-30.50-28.87-36.73--
Return on Invested Capital-99.95-53.63-25.89-30.34-17.26-182.39-48.03
Quick Ratio5.717.1611.979.2515.151.965.66
Current Ratio5.717.1611.979.2515.151.965.66

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-102.47-148.12-149.10-102.07-99.42-66.92-34.31-23.43
Depreciation2.553.653.933.523.640.980.900.75
Other Funds (Non Cash)10.2933.9712.0912.579.024.350.02-1.06
Funds from Operations-89.63-110.51-133.09-85.97-86.86-61.27-33.39-23.74
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-3.48-0.48-5.11-7.32-4.1128.750.18-8.27
Cash from Operating Activities-93.11-110.99-138.20-93.29-90.97-32.52-33.22-32.01
Capital Expenditures0.12-1.36-4.88-11.61-6.45-2.12-0.32-0.88
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.320.000.010.000.000.000.010.00
Purchase or Sale of Investments79.85103.6093.10-56.57-86.19-173.280.000.00
Purchase of Investments-102.56-149.23-304.39-394.76-339.06-173.280.000.00
Sale Or Maturity of Investments182.41252.83397.49338.19252.870.000.000.00
Other Uses0.000.00-1.620.00-0.60-1.00-1.000.00
Other Sources0.000.000.000.000.000.007.6728.12
Cash from Investing Activities80.29102.2486.61-68.18-93.25-176.406.3627.23
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock27.694.8216.72154.302.13432.400.270.22
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock27.694.8216.72154.302.13432.400.270.22
Proceedsfrom Stock Options27.664.8216.11152.720.00429.850.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.001.031.47-0.04
Change in Long Term Debt0.000.000.000.000.001.031.47-0.04
Issuance of Long Term Debt0.000.000.000.000.001.151.580.00
Reduction of Long Term Debt0.000.000.000.000.00-0.12-0.11-0.04
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities27.694.8216.72154.302.13433.431.740.17
Net Change in Cash14.87-3.93-34.87-7.18-182.08224.51-25.12-4.60
Free Cash Flow-92.99-112.35-143.08-104.90-97.42-34.64-33.53-32.89
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.00-0.100.320.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments94.80112.31117.63139.34147.26183.95
Short Term Receivables1.791.942.362.982.932.78
Inventories0.000.000.000.000.000.00
Other Current Assets3.492.342.392.915.325.78
Total Current Assets100.08116.59122.38145.23155.51192.51
Net Property, Plant & Equipment21.5722.5323.4824.4323.6024.64
Total Investments and Advances0.001.501.003.5512.100.18
Deferred Tax Assets---4.26--
Other Assets1.382.142.142.153.783.58
Total Assets123.03142.77149.00179.63194.98220.90
Short Term Debt Incl. Current Port. of LT Debt1.461.381.291.202.692.29
Accounts Payable5.053.083.505.783.803.24
Other Current Liabilities13.6413.5214.8818.4321.5723.36
Total Current Liabilities20.1417.9719.6725.4128.0628.89
Long Term Debt24.8825.2825.6626.0322.7823.56
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---4.260.550.55
Other Liabilities1.371.421.651.751.761.77
Total Liabilities46.3944.6746.9857.4653.1454.77
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity76.6398.10102.02122.17141.84166.13
Total Shareholders Equity76.6398.10102.02122.17141.84166.13
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity76.6398.10102.02122.17141.84166.13
Total Liabilities & Stockholders Equity123.03142.77149.00179.63194.98220.90
Book Value Per Share0.710.931.051.281.521.78
Tangible Book Value Per Share0.710.931.051.281.521.78
Full-Time Employees---97--
Price to Book Ratio0.551.671.481.051.310.54
Return on Assets-64.44-56.87-63.04-59.19-58.27-55.32
Return on Equity-93.80-78.27-83.46-78.97-74.28-68.93
Return on Invested Capital-26.21-19.68-19.65-17.87-16.73-28.52
Quick Ratio4.976.496.225.715.546.66
Current Ratio4.976.496.225.715.546.66

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-26.61-24.28-25.09-26.49-27.55-54.10
Depreciation0.590.620.650.680.631.17
Other Funds (Non Cash)2.022.752.403.123.1424.12
Funds from Operations-24.01-20.90-22.03-22.69-23.78-28.81
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.49-1.88-4.951.87-1.410.55
Cash from Operating Activities-22.52-22.79-26.98-20.82-25.18-28.26
Capital Expenditures-0.02-0.00-0.070.22-0.12-0.42
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.320.000.000.000.000.00
Purchase or Sale of Investments19.0918.9424.0617.7510.9724.45
Purchase of Investments-15.94-20.50-22.09-44.03-57.45-32.22
Sale Or Maturity of Investments35.0339.4546.1461.7968.4156.67
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities19.3918.9423.9817.9710.8524.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.9917.942.704.070.280.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.9917.942.704.070.280.01
Proceedsfrom Stock Options2.9817.922.694.070.280.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.9917.942.704.070.280.01
Net Change in Cash-0.1414.09-0.301.22-14.06-4.22
Free Cash Flow-22.54-22.79-27.06-20.61-25.30-28.68

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 9.99M 2025: 11.16M
Non-US2024: 724.00K 2025: 1.68M
United States2024: 9.27M 2025: 9.48M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.15%14.9M98.3M2.57M
2026-10-1512.87%12.6M97.6M2.35M
2026-09-3013.24%12.9M97.6M1.32M
2026-09-1513.30%13.0M97.6M1.67M
2026-08-3112.92%12.5M96.8M1.75M
2026-08-1412.88%12.5M96.8M1.90M
2026-07-3113.00%11.6M89.5M1.99M
2026-07-1512.95%11.6M89.5M2.07M
2026-06-3010.75%9.6M89.5M1.88M
2026-06-158.41%7.5M89.5M1.54M
2026-05-298.35%7.5M89.2M1.42M
2026-05-158.00%7.1M89.2M1.41M
2026-04-308.07%7.1M88.3M1.37M
2026-04-157.87%6.8M86.0M1.27M
2026-03-317.53%6.5M85.9M1.23M
2026-03-138.21%7.1M85.9M1.22M
2026-02-278.42%7.2M85.9M1.18M
2026-02-139.35%7.8M83.1M1.08M
2026-01-309.10%7.5M82.8M2.28M
2026-01-158.21%6.8M82.8M2.21M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.050.202.98455.000.000.437-0.0040.000
call1.000.000.050.055.66633.000.000.310-0.0070.000
call1.500.000.050.056.9041210.000.281-0.0080.000
call2.000.000.050.007.7030.000.000.267-0.0090.000
call2.500.000.050.008.2880.000.000.257-0.0090.000
call5.000.000.750.0010.7380.000.000.245-0.0120.000
call7.500.000.750.0011.6760.000.000.236-0.0120.000
put0.500.001.000.053.0947.000.00-0.573-0.0050.000
put1.000.151.150.000.0000.000.00-0.685-0.0080.000
put1.500.601.600.700.00030.000.00-0.712-0.0090.000
put2.001.152.150.000.0000.000.00-0.726-0.0090.000
put2.501.802.800.000.0000.000.00-0.735-0.0100.000
put5.003.207.004.650.0000.000.00-0.755-0.0110.000
put7.506.809.507.150.0000.000.00-0.764-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-068-KCurrent report2026-10-02SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-27SCHEDULE 13GSEC
2026-06-188-KCurrent report2026-06-17SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-06-05DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-01DEFR14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-24ARSAnnual report to security holders. 2025-12-31SEC
2026-04-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-12-31SEC
2026-04-10PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-12-31SEC
2026-03-318-KCurrent report2026-03-31SEC
2026-03-0510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-058-KCurrent report2026-03-05SEC
2026-03-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-25SEC
2026-02-25144Filing for proposed sale of securities under Rule 144.SEC
2026-02-25144Filing for proposed sale of securities under Rule 144.SEC
2026-02-25144Filing for proposed sale of securities under Rule 144.SEC
2026-02-244Statement of changes in beneficial ownership of securities2026-02-20SEC
2026-02-244Statement of changes in beneficial ownership of securities2026-02-20SEC
2026-02-244Statement of changes in beneficial ownership of securities2026-02-20SEC
2026-02-244Statement of changes in beneficial ownership of securities2026-02-20SEC
2026-02-204Statement of changes in beneficial ownership of securities2026-02-20SEC
2026-02-204Statement of changes in beneficial ownership of securities2026-02-20SEC
2026-02-204Statement of changes in beneficial ownership of securities2026-02-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020047.47K5
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.7.88%
PFIZER INC4.73%
VANGUARD CAPITAL MANAGEMENT LLC4.24%
MACKENZIE FINANCIAL CORP3.80%
RENAISSANCE TECHNOLOGIES LLC2.80%
Kynam Capital Management, LP2.52%
GEODE CAPITAL MANAGEMENT, LLC2.27%
STATE STREET CORP1.65%
BANK OF AMERICA CORP /DE/1.42%
ACADIAN ASSET MANAGEMENT LLC1.36%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.04%
iShares Russell 2000 ETF2.31%
VANGUARD EXTENDED MARKET INDEX FUND1.12%
Fidelity Small Cap Index Fund1.01%
iShares Russell 2000 Value ETF0.89%
iShares Biotechnology ETF0.63%
VANGUARD RUSSELL 2000 INDEX FUND0.49%
Fidelity Extended Market Index Fund0.42%
Schwab U.S. Small-Cap ETF0.39%
iShares Micro-Cap ETF0.31%

OakChart. CRBU. Cached 15 minutes.